MCM
PGNX

Manchester Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Manchester Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,020
Closed -$14K – 676
2019
Q1 		$14K Buy
+3,020
New +$13.7K ﹤0.01% 543

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Manchester Capital Management's PGNX Position: Q2 2019 in Review

Manchester Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2019, closing a stake of 3,020 shares — an estimated $14K sold.

Manchester Capital Management first reported a position in PGNX in Q1 2019 and held it in 1 quarter. The position peaked at $14K in Q1 2019. 142 funds tracked by Wall St. Rank hold PGNX as of Q2 2019.

  • Manchester Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2019 after selling out during the quarter.
  • Manchester Capital Management sold 3,020 Progenics Pharmaceuticals Inc shares in Q2 2019, an estimated $14K.
  • Manchester Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2019 and held it in 1 quarter.
  • Manchester Capital Management's Progenics Pharmaceuticals Inc position peaked at $14K in Q1 2019.
  • 142 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2019.

Based on Manchester Capital Management's 13F filing for Q2 2019, filed 5 Aug 2019.